The case for & against
Bull & Bear analysis
Bearish
Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leader in genomics, specializes in long-read sequencing technologies that enhance the understanding of genetic variations and their implications on human health. With a focus on clinical sequencing markets and expanding its position in population-scale genomic programs, PACB aims to leverage its innovative platforms, such as the recently launched Spark Next chemistry. However, it is currently navigating significant operational challenges, transitioning out of older systems, while seeking to enhance its clinical adoption.
Bull says
- ↑Spark Next chemistry launch drives strong clinical adoption
- ↑Consumables revenue rose 6% YoY; clinical consumables up 67%
- ↑P/B ratio of 0.34 suggests undervaluation relative to assets
- ↑$237M cash position supports operations; positive liquidity profile
- ↑Management refocus under new CEO on efficiency and growth
- ↑Long-read tech differentiation primes PACB for multi-omics leadership
Bear says
- ↓Revised 2026 revenue guidance $155–165M on funding headwinds
- ↓Q2 revenue $39M missed estimates; instrument sales down 9% YoY
- ↓Cash-flow breakeven deferred to 2028, net loss widening
- ↓Over 60% of placements to new customers risks inconsistent uptake
- ↓Weak profitability and negative earnings yield raise sustainability concerns
- ↓High volatility and low institutional ownership deter investors
Investment themes with PACB
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Julian Komar's Best Winners (Screen Results)↓ -0.50%
NVDA · GOOGL · AVGO
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 05-09-2025neutral
Transcript signals
Bull points
- we're addressing the upfront CapEx barrier some customers face when assessing HiFi, and we're doing this by implementing promotions that ease customers' upfront CapEx requirements and we're doing this in ways that preserve PacBio's overall economic value.
- we are investing in developing library prep and informatics solutions around Revio that enhance the platform's value proposition.
- We believe our current sales pipeline is sufficient to at least support the midpoint of our guide of 120 Revio systems, which provides further confidence in our revised revenue targets for 2024.
Bear points
- revenue of $38.8 million for the first quarter was below expectations due to an increasing number of customers delaying instrument purchases and softness in consumable shipments.
- we expect full-year revenue to be in the range of $170 million to $200 million. The instrument shortfall primarily resulted from elongated customer purchasing cycles, as the median sales cycle for Revio instrument purchases increased more than we expected in the first quarter of 2024.
- we believe that the sales cycle increased primarily because of uncertainty surrounding the timing of funding for new capital equipment, particularly in the United States and China, smaller Sequel II and IIe customers who are planning to upgrade to a Revio are waiting for the samples to drive that upgrade, and an increasing proportion of the sales pipeline is comprised of new customers in the first quarter of 2024, which have proven to have longer sales cycles compared to those existing PacBio customers.
Read full transcript analysis ›